Xeris Pharmaceuticals Inc traded at $10.20 this Friday October 23rd, decreasing $0.66 or 6.08 percent since the previous trading session. Looking back, over the last four weeks, Xeris Pharmaceuticals lost 13.97 percent. Over the last 12 months, its price rose by 10.75 percent. Looking ahead, we forecast Xeris Pharmaceuticals Inc to be priced at 10.09 by the end of this quarter and at 9.47 in one year, according to Trading Economics global macro models projections and analysts expectations.
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.